Skip to Main Content
ADVERTISEMENT
SCROLL TO CONTINUE WITH CONTENT



Property Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes
Advertisement
Close
  • Home
  • Articles and Issues
    • Back
    • Current Issue
    • Articles in Press
    • List of Issues
  • Collections
  • GenePod
  • For Authors
    • Back
    • Author Information
    • Permissions
    • Researcher Academy 
    • Submit A Manuscript 
  • Journal Info
    • Back
    • About the Journal
    • Contact Information
    • Editorial Board
  • 2023 Media Kit
  • Subscribe
  • Submit Your Manuscript 
Advanced searchSave search

Please enter a term before submitting your search.

Ok
  • ACMG Homepage         Submit
  • Log in
  • Register
  • Log in
    • ACMG Homepage         Submit
    • Log in
  • Subscribe
Skip menu
    x

    Filter:

    Filters applied

    • ACMG Statements and Guidelines
    • McDowell, Geraldine ARemove McDowell, Geraldine A filter
    • Palomaki, Glenn ERemove Palomaki, Glenn E filter
    Clear all

    Article Type

    • Research Article3

    Publication Date

    Author

    • Bradley, Linda A2
    • Canick, Jacob A1
    • Donnenfeld, Alan E1
    • Lee, Jo Ellen S1

    Journal

    • Genetics in Medicine3

    Keyword

    • Down syndrome2
    • genetic screening2
    • maternal serum screening2
    • prenatal diagnosis2
    • first trimester1
    • maternal serum1
    • nuchal translucency1
    • open neural tube defects1
    • prenatal screening1

    ACMG Statements and Guidelines

    These online statements and guidelines are definitive and may be cited using the digital object identifier (DOI). These recommendations are designed primarily as an educational resource for medical geneticists and other healthcare providers to help them provide quality medical genetics services; they should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. Please refer to the leading disclaimer in each document for more information.

    3 Results
    Subscribe to collection
    • Export
      • PDF
      • Citation

    Please select at least one article in order to proceed.

    Ok
    FilterHide Filter
    • ACMG Standards and Guidelines
      Open Archive

      Technical standards and guidelines: Prenatal screening for Down syndrome that includes first-trimester biochemistry and/or ultrasound measurements

      Genetics in Medicine
      Vol. 11Issue 9p669–681Published in issue: September, 2009
      • Glenn E. Palomaki
      • Jo Ellen S. Lee
      • Jacob A. Canick
      • Geraldine A. McDowell
      • Alan E. Donnenfeld
      • for the ACMG Laboratory Quality Assurance Committee
      Cited in Scopus: 37
      • Preview Hide Preview
      • Download PDF
      • Export Citation
        This statement is intended to augment the current general ACMG Standards and Guidelines for Clinical Genetics Laboratories and to address guidelines specific to first-trimester screening for Down syndrome. The aim is to provide the laboratory the necessary information to ensure accurate and reliable Down syndrome screening results given a screening protocol (e.g., combined first trimester and integrated testing). Information about various test combinations and their expected performance are provided, but other issues such as availability of reagents, patient interest in early test results, access to open neural tube defect screening, and availability of chorionic villus sampling are all contextual factors in deciding which screening protocol(s) will be selected by individual health care providers.
      • ACMG Standards and Guidelines
        Open Archive

        Technical standards and guidelines: Prenatal screening for open neural tube defects: This new section on “Prenatal Screening for Open Neural Tube Defects,” together with the new section on “Prenatal Screening for Down Syndrome,” replaces the previous Section H of the American College of Medical Genetics Standards and Guidelines for Clinical Genetics Laboratories

        Genetics in Medicine
        Vol. 7Issue 5p355–369Published in issue: May, 2005
        • Linda A. Bradley
        • Glenn E. Palomaki
        • Geraldine A. McDowell
        • ONTD Working Group
        • ACMG Laboratory Quality Assurance Committee
        Cited in Scopus: 16
        • Preview Hide Preview
        • Download PDF
        • Export Citation
          This specific technical standards and guidelines statement is intended to augment the current general American College of Medical Genetics (ACMG) Standards and Guidelines for Clinical Genetics Laboratories and to address validation guidelines specific to second trimester maternal serum screening. Individual laboratories are responsible for meeting the CLIA/CAP quality assurance standards with respect to appropriate sample documentation, assay validation, general proficiency, and quality control measures.
        • ACMG Standards and Guidelines
          Open Archive

          Technical standards and guidelines: Prenatal screening for Down syndrome: This new section on “Prenatal Screening for Down Syndrome,” together with the new section on “Prenatal Screening for Open Neural Tube Defects,” replaces the previous Section H of the American College of Medical Genetics Standards and Guidelines for Clinical Genetics Laboratories

          Genetics in Medicine
          Vol. 7Issue 5p344–354Published in issue: May, 2005
          • Glenn E. Palomaki
          • Linda A. Bradley
          • Geraldine A. McDowell
          • Down Syndrome Working Group
          • ACMG Laboratory Quality Assurance Committee
          Cited in Scopus: 17
          • Preview Hide Preview
          • Download PDF
          • Export Citation
            This statement is intended to augment the current general American College of Medical Genetics (ACMG) Standards and Guidelines for Clinical Genetics Laboratories and to address validation guidelines specific to second trimester maternal serum screening for Down syndrome. Individual laboratories are responsible for meeting the CLIA/CAP quality assurance standards with respect to appropriate sample documentation, assay validation, general proficiency, and quality control measures.
          Page 1 of 1

          Login to your account

          Show
          Forgot password?
          Don’t have an account?
          Create a Free Account

          If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password

          If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password

          Cancel
          • Home
          • Articles and Issues
          • Current Issue
          • Articles in Press
          • List of Issues
          • Collections
          • GenePod
          • For Authors
          • Permissions
          • Researcher Academy
          • Journal Info
          • About the Journal
          • Activate Online Access
          • ACMG Career Center
          • Advertise in Genetics in Medicine
          • Contact Information
          • Editorial Board
          • Reprints
          • New Content Alerts
          • 2023 Media Kit
          • Subscribe
          • More Periodicals
          • Find a Periodical
          • Go to Product Catalog
          We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
          Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.

          • Privacy Policy  
          • Terms and Conditions  
          • Accessibility  
          • Help & Contact

          RELX